Anemia is a condition of iron deficiency affecting large fraction of population including children, pregnant women and menstruating women. It prevent the adequate supply of the oxygen to the tissues leading to palpitations, weakness, light-headedness etc. The vitamin B12 test will help to diagnose the cause of anemia and neuropathy and to monitor the effectiveness of B12 deficiency or folate deficiency treatment whereas the folic acid levels will help to detect folate deficiency and monitor folate deficiency therapy. There are various types of anaemia such as vitamin deficiency anemia linked with B12, anemia due to low ferritin levels etc.
Carlo Rosa, the CEO of the DiaSorin Group commented " I am particularly proud of the launch of the Vitamin B12 and Folate tests that allow us to enrich our offer in Europe with a new test panel for anaemia diagnosis, the development of new products and entrance into new clinical areas, one of the pillars of our growth, will continue to be one of the main drivers of our development also in the future."
According to the Axiom Market Research & Consulting‘s market research analyst the clinical chemistry segment is expected to progress at a CAGR of 4.74% during the forecast period attributing to increasing rate of nutritional deficiency and increase in prevalence of chronic diseases and unhealthy life styles.
DiaSorin S.p.A was founded in 1968 and headquartered in Saluggia, VC Italy. It is a biotechnology based company operating its business in vitro diagnostic, immunoassay, molecular diagnostic, blood tests, GI stool testing, vitamin D, prenatal screening, and infectious diseases. The company develop, produce and market reagent kits for IVD globally and has its presence in continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers worldwide. The research and development department is focusing on new test for in vitro diagnosis to enhance the company’s market share in South Asia region.